Last updated: July 28, 2026
What was decided in AstraZeneca AB v. Mylan Pharmaceuticals Inc. (3:15-cv-03384) and what patents were at issue?
Executive summary. The provided case identifier (“3:15-cv-03384”) is insufficient to produce a litigation summary and patent-by-patent analysis. A complete, accurate response requires the underlying docket record (court, district, caption details, asserted patents, claim construction outcomes, filing dates for the complaint/amended complaints, dispositive motion results, settlement or judgment terms, and final disposition). Those facts are not present in the prompt, so a litigation-focused analysis cannot be generated without risking errors.
Which patents were asserted in AstraZeneca AB v. Mylan Pharmaceuticals Inc. 3:15-cv-03384?
Answer (based on provided information). Not determinable from the input.
What Orange Book-listed drugs and listed patents were implicated?
Not determinable from the input.
Was the dispute about ANDA Paragraph IV, a settlement, or an infringement judgment?
Not determinable from the input.
What did the court rule in AstraZeneca AB v. Mylan Pharmaceuticals Inc. (3:15-cv-03384)?
Answer (based on provided information). Not determinable from the input.
Were there claim construction decisions (Markman orders)?
Not determinable from the input.
Were there summary judgment rulings on infringement or validity?
Not determinable from the input.
Did the case end in settlement or final judgment?
Not determinable from the input.
When did the parties litigate and what were the key procedural milestones?
Answer (based on provided information). Not determinable from the input.
Complaint, amended complaint, and answer dates
Not determinable from the input.
Infringement contentions and invalidity contentions
Not determinable from the input.
Daubert or expert admissibility rulings
Not determinable from the input.
How strong was AstraZeneca’s asserted patent estate in this case?
Answer (based on provided information). Not determinable from the input.
Validity attack themes (anticipation, obviousness, enablement)
Not determinable from the input.
Infringement theories (product, method, formulation, dosage regimen)
Not determinable from the input.
Court treatment of written description, indefiniteness, and prosecution history estoppel
Not determinable from the input.
How did Mylan’s defenses and litigation strategy affect outcomes?
Answer (based on provided information). Not determinable from the input.
Claim scope arguments
Not determinable from the input.
Non-infringement positions tied to ANDA formulation or manufacturing
Not determinable from the input.
Design-around attempts and late-stage amendments
Not determinable from the input.
Did any Paragraph IV settlement drive a generic or follow-on launch date risk profile?
Answer (based on provided information). Not determinable from the input.
Cease-and-desist triggers and market-entry timing
Not determinable from the input.
Triggering events for lifting restrictions
Not determinable from the input.
What is the regulatory posture (FDA pathway) connected to the litigation?
Answer (based on provided information). Not determinable from the input.
ANDA number, suitability, and FDA exclusivity interaction
Not determinable from the input.
Orange Book listing status during the case
Not determinable from the input.
What generic entry risks exist for the drug at issue based on this litigation?
Answer (based on provided information). Not determinable from the input.
If AstraZeneca won: import of injunctions or ongoing royalty exposure
Not determinable from the input.
If Mylan prevailed: invalidity effect on other ANDAs
Not determinable from the input.
Key Takeaways
No litigation summary can be produced from the provided inputs without the docket-level facts needed to identify (1) the asserted patents, (2) the procedural posture, and (3) the final outcomes.
FAQs
- What patents were listed in the Orange Book for the NDA/ANDA tied to 3:15-cv-03384?
- Did the case involve a Paragraph IV certification and what was the launch calendar impact?
- Were there claim construction holdings that narrowed or broadened the asserted claims?
- What defenses (invalidity or non-infringement) were central to Mylan’s case?
- Did the matter end in settlement, and did it include covenants not to sue or payment terms?
References (APA)
- Not available from the provided information.
